Literature DB >> 19142099

Mortality rates among patients with schizophrenia and tardive dyskinesia.

Siow-Ann Chong1, Jenny A M Tay, Mythily Subramaniam, Elaine Pek, David Machin.   

Abstract

Tardive dyskinesia (TD) is a severe and potentially irreversible movement, and previous studies have suggested increased mortality among patients with TD, but most of these studies are limited by small sample sizes and short periods of follow-up. This study examined the mortality rate of a cohort of 608 Asian patients with schizophrenia during a 6-year period and used survival analyses on time from case ascertainment to outcome (death). Data on the survival status were collected and compared between those with and without TD, and cross-tabulation was performed to show the correlation between survival and mortality rates among patients with and without TD.Seventy-two patients died, 39 (54.2%) of whom had TD previously. Of the 536 surviving cases, 239 (44.6%) have TD. The mortality rates between those with TD and those without TD were statistically significant (hazard ratio, 2.62; 95% confidence interval, 1.58-4.33; P = 0.0006).The mortality rate was dependent on age; nevertheless, the adverse effect of TD on survival rate, although reduced, remains after controlling for age (hazard ratio, 1.90; 95% confidence interval, 1.12-3.20; P = 0.017). Our finding showed a robust association with increased mortality rate and TD, but we failed to find any significant association with any specific cause of death and TD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19142099     DOI: 10.1097/JCP.0b013e3181929f94

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  16 in total

1.  Perspectives from resource poor settings.

Authors:  Pratap Sharan
Journal:  World Psychiatry       Date:  2017-02       Impact factor: 49.548

2.  Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.

Authors:  Stanley N Caroff; Vicki G Davis; Del D Miller; Sonia M Davis; Robert A Rosenheck; Joseph P McEvoy; E Cabrina Campbell; Bruce L Saltz; Silvana Riggio; Miranda H Chakos; Marvin S Swartz; Richard S E Keefe; T Scott Stroup; Jeffrey A Lieberman
Journal:  J Clin Psychiatry       Date:  2010-08-10       Impact factor: 4.384

Review 3.  The genetics of drug-related movement disorders, an umbrella review of meta-analyses.

Authors:  Nadine C van der Burg; Asmar F Y Al Hadithy; Peter N van Harten; Jim van Os; P Roberto Bakker
Journal:  Mol Psychiatry       Date:  2020-02-04       Impact factor: 15.992

4.  Genome wide study of tardive dyskinesia in schizophrenia.

Authors:  Keane Lim; Max Lam; Clement Zai; Jenny Tay; Nina Karlsson; Smita N Deshpande; B K Thelma; Norio Ozaki; Toshiya Inada; Kang Sim; Siow-Ann Chong; Todd Lencz; Jianjun Liu; Jimmy Lee
Journal:  Transl Psychiatry       Date:  2021-06-08       Impact factor: 6.222

Review 5.  Mortality in schizophrenia: a measurable clinical endpoint.

Authors:  Chris J Bushe; Mark Taylor; Jari Haukka
Journal:  J Psychopharmacol       Date:  2010-11       Impact factor: 4.153

6.  Long-stay psychiatric patients: a prospective study revealing persistent antipsychotic-induced movement disorder.

Authors:  P Roberto Bakker; Izaäk W de Groot; Jim van Os; Peter N van Harten
Journal:  PLoS One       Date:  2011-10-03       Impact factor: 3.240

Review 7.  Miscellaneous treatments for antipsychotic-induced tardive dyskinesia.

Authors:  Karla Soares-Weiser; John Rathbone; Yusuke Ogawa; Kiyomi Shinohara; Hanna Bergman
Journal:  Cochrane Database Syst Rev       Date:  2018-03-19

Review 8.  Cholinergic medication for antipsychotic-induced tardive dyskinesia.

Authors:  Irina Tammenmaa-Aho; Rosie Asher; Karla Soares-Weiser; Hanna Bergman
Journal:  Cochrane Database Syst Rev       Date:  2018-03-19

Review 9.  Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia.

Authors:  Hany G El-Sayeh; John Rathbone; Karla Soares-Weiser; Hanna Bergman
Journal:  Cochrane Database Syst Rev       Date:  2018-01-18

10.  Assesment of Risk Factors for Tardive Dyskinesia.

Authors:  Melek Kanarya Vardar; Mehmet Emin Ceylan; Bariş Önen Ünsalver
Journal:  Psychopharmacol Bull       Date:  2020-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.